Monopar Therapeutics Inc (MNPR)
NASDAQ:MNPR
Total Valuation
Monopar Therapeutics Inc has a market cap or net worth of $388.34M. The enterprise value is -$61.29B.
Market Cap$388.34M
Enterprise Value-$61.29B
Share Statistics
Monopar Therapeutics Inc has 6,692,140 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding6,692,140
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Monopar Therapeutics Inc’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is -0.01%.
Return on Equity (ROE)>-0.01
Return on Assets (ROA)>-0.01
Return on Invested Capital (ROIC)-0.01%
Return on Capital Employed (ROCE)>-0.01
Revenue Per Employee0.00
Profits Per Employee-979.78M
Employee Count14
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Monopar Therapeutics Inc is ―. Monopar Therapeutics Inc’s PEG ratio is -0.98.
PE Ratio―
PS Ratio0.00
PB Ratio<0.01
Price to Fair Value<0.01
Price to FCF-0.04
Price to Operating Cash Flow-29.40
PEG Ratio-0.98
Income Statement
In the last 12 months, Monopar Therapeutics Inc had revenue of 0.00 and earned -13.72M in profits. Earnings per share was -1.85.
Revenue0.00
Gross Profit0.00
Operating Income-16.70M
Pretax Income-13.72M
Net Income-13.72M
EBITDA-16.70M
Earnings Per Share (EPS)-1.85
Cash Flow
In the last 12 months, operating cash flow was -12.20M and capital expenditures -3.00, giving a free cash flow of -12.20M billion.
Operating Cash Flow-12.20M
Free Cash Flow-12.20M
Free Cash Flow per Share-1.82
Dividends & Yields
Monopar Therapeutics Inc pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.65
52-Week Price Change77.90%
50-Day Moving Average57.88
200-Day Moving Average61.13
Relative Strength Index (RSI)41.57
Average Volume (3m)175.07K
Important Dates
Monopar Therapeutics Inc upcoming earnings date is May 7, 2026, Before Open (Confirmed).
Last Earnings DateMar 27, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Monopar Therapeutics Inc as a current ratio of 51.35, with Debt / Equity ratio of 0.11%
Current Ratio51.35
Quick Ratio51.35
Debt to Market Cap0.32
Net Debt to EBITDA3.69K
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Monopar Therapeutics Inc has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Monopar Therapeutics Inc EV to EBITDA ratio is 3.66K, with an EV/FCF ratio of 5.02.
EV to Sales0.00
EV to EBITDA3.66K
EV to Free Cash Flow5.02
EV to Operating Cash Flow5.02
Balance Sheet
Monopar Therapeutics Inc has $61.83B in cash and marketable securities with $154.92M in debt, giving a net cash position of $61.68B billion.
Cash & Marketable Securities$61.83B
Total Debt$154.92M
Net Cash$61.68B
Net Cash Per Share$9.22K
Tangible Book Value Per Share$18.60K
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Monopar Therapeutics Inc is $111.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$111.00
Price Target Upside91.28% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast―
EPS Growth Forecast-73.48%